Roche Backs Off Mircera Suit In India
This article was originally published in PharmAsia News
Roche has dropped its suit against Intas Pharmaceuticals over the alleged infringement of its patents pertaining to Mircera, after the Indian firm apparently established that its product is "different". But both sides appear keen to keep the matter alive, suggesting that they would seek appropriate remedies in the event of fresh "cause of action".
You may also be interested in...
Eris Lifesciences has acquired a Novartis trademark for vildagliptin, a DPP-4 inhibitor that has been the subject of a torrent of alleged infringement-related legal action in India. Pricing for the acquired brand will be interesting to watch from now on as a patent on vildagliptin is set to expire soon.
Cipla’s global chief operating officer is leaving the company to pursue new interests, amid a spate of top-level exits that have marked the pharma sector in India in 2019.
Remogliflozin prescriptions gallop in India and Glenmark expects the ‘affordable’ therapy to take share from other SGLT2 inhibitors.